Thermal readout · Mitochondrial-derived peptide
MOTS-c peptide is a mitochondrial-derived signal studied for metabolism, muscle preservation, and exercise capacity.
A spare, cited read of the published animal and cell literature — each finding logged at its true evidence temperature, with the research-use and FDA status read first.
The short version
MOTS-c peptide is a tiny protein your own mitochondria make. Mitochondria are the parts of a cell that turn food into usable energy, and MOTS-c is one of a handful of signals they release. It is 16 amino acids long, and in animals it acts like a low-fuel alarm: it switches on AMPK (the enzyme a cell uses to sense when energy is running low), which improves how the body handles blood sugar. Almost everything measured so far comes from mice and cells. There are no completed human trials, and it is sold only for laboratory research.
What Is MOTS-c?
MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1) [1]. That origin is unusual: most peptides are written in the cell's main DNA, in the nucleus, while MOTS-c is written in the separate genome carried inside the mitochondrion. It belongs to a small family called mitochondrial-derived peptides (MDPs) — short signals encoded within mitochondrial DNA — and is distinct from the better-known humanin and from the SHLP peptides in the same family [7]. The peptide is highly conserved across mammals and is detectable in human plasma and skeletal muscle, where its levels rise with exercise and shift with age and metabolic state [4].
The research is anchored in molecular detail: a molecular weight of 2174.61 Da and the CAS identifier 1627580-64-6. Those numbers, and the dose figures throughout this digest, are drawn from published animal and cell studies — they are reference points for the literature, not instructions for use. For where it sits in the broader record, see the MOTS-c muscle preservation research and the MOTS-c mechanism of action.
What Does MOTS-c Do?
What Does MOTS-c Do?
MOTS-c inhibits the folate cycle (a set of chemical reactions that supply building blocks for DNA) and de novo purine biosynthesis, which raises a molecule called AICAR and activates AMPK — improving glucose handling and insulin sensitivity primarily in skeletal muscle in animal models [1]. Insulin sensitivity is simply how readily cells respond to insulin and pull sugar out of the blood. Under metabolic stress the peptide also moves into the cell nucleus and helps regulate stress-response genes [3]. These are molecular actions measured in cells and animals, not demonstrated human outcomes.
The founding study showed that MOTS-c treatment prevented diet-induced obesity and high-fat-diet-induced insulin resistance in mice, identifying skeletal muscle as the primary target organ and AMPK as the downstream effector [1]. Later work added an exercise dimension: the body makes more of its own MOTS-c during physical activity, and giving it to mice improved physical performance across young, middle-aged, and old animals [2].
What the MOTS-c Literature Has Measured
The strongest results cluster in three areas. In metabolism, MOTS-c prevented diet-induced obesity and improved insulin sensitivity in mice [1]. In exercise capacity, exogenous MOTS-c significantly increased treadmill running capacity in aged mice at P=0.000002, alongside gains in grip strength and gait [2]. In muscle preservation, it reduced myostatin and muscle-atrophy signaling [6] and, in a 2024 study, prevented skeletal-muscle atrophy while enhancing muscle glucose uptake by directly binding and activating casein kinase 2 (CK2) [9].
What the literature has not produced is human evidence of benefit. Every interventional finding above is from cells or animals; the human data are observational biomarker associations only [4]. The most candid framing — and the one this digest keeps — is that the molecular case is reproducible and the human case is unwritten. For the full breakdown, read the MOTS-c research summary; for atrophy and disuse specifically, the MOTS-c muscle preservation research.
Where the Cold Readings Are
Three facts sit at the cold end of the scale and are stated first, not buried. There are no completed human efficacy or safety trials of exogenous MOTS-c [4]. There is no validated human pharmacokinetic half-life, so the rodent doses in the literature cannot be extrapolated to people. And MOTS-c is not an FDA-approved drug for any use — it is sold only as a research chemical for laboratory work, of unregulated purity, and is treated as a prohibited substance in elite sport.
This site is an independent editorial digest. It does not sell MOTS-c, does not recommend any supplier, and does not provide medical or dosing guidance. For the regulatory picture in full, see MOTS-c legal status and 503A access and MOTS-c and anti-doping status; for the dose figures as they appear in animal research, see MOTS-c dosage in the literature; and for quick answers, the frequently asked questions.